Considering that STING agonists cover the advantages and challenges of the most immune activation adjuvants, and STING agonists are taken as a representative in the subsequent part of this review to discuss the potential of lipid‐NPs application in cancer immunotherapy. The gene discussed is STING1; the disease is cancer.